BioSpace News Archive

Drug Development

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

The study was selected for oral presentation today at the American Association for Cancer Research Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting in Orlando, Florida.

December 5, 2017

·

5 min read

Stryker Nabs FDA OK for Cementless Mako Total Knee

FDA

In2Bones Announces FDA Clearance of the CoLink View “See-Through” Plating System

The CoLink View is the sixth In2Bones PEEK-related implant system that has received FDA clearance; others are expected to be cleared in 2018.

December 5, 2017

·

3 min read

Genetown

Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition

Acceleron Pharma will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th ASH Annual Meeting and Exposition taking place December 9-12, 2017 in Atlanta, Georgia.

December 5, 2017

·

1 min read

Pharm Country

Celgene Launches Celgene Cancer Care Links to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries

Celgene Corporation today announced the launch of Celgene Cancer Care Links, a new grant program designed to support cancer healthcare capacity building in resource-constrained countries around the world.

December 5, 2017

·

4 min read

Sanofi and IBM Watson Health Real-World Analysis Showed That Individuals Not Achieving Control on Basal Insulin Within 12 Months Were Unlikely to Achieve Control During the Remainder of the Two Year Study

The likelihood of responding to basal insulin in routine care in the U.S. declined rapidly when blood sugar control was not achieved within the first 12 months after starting treatment.

December 5, 2017

·

6 min read

Dynatronics Announces Conversion of Series C and Series D Preferred Shares

Dynatronics today announced the automatic conversion of 1.3 million shares of Series C Preferred Stock and 1.6 million shares of Series D Preferred Stock to Common Stock following its Annual Meeting of Shareholders held November 29, 2017.

December 5, 2017

·

3 min read

FDA Advisory Committee Scheduled to Review Lipocin

Drug Development

Galectin Tanks as NASH Drug Flunks Phase IIb Trial

There was a positive trend in the total group of patients but the difference did not reach statistical significance for this primary endpoint.

December 5, 2017

·

10 min read

Drug Development

Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase I/II Clinical Trial for A1AT Deficiency

The ADVANCE clinical trial is designed to evaluate the safety and protein expression following a single administration of ADVM-043, Adverum’s novel gene therapy candidate.

December 5, 2017

·

6 min read

Business

Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors

From 2003 through its acquisition by Merck in 2014, Mr. Bonney was the chief executive officer of Cubist Pharmaceuticals.

December 5, 2017

·

5 min read

Drug Development

100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

In the Phase 1 clinical trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing prostate specific antigen (PSA) were treated with six intradermal injections of ProscaVax.

December 5, 2017

·

4 min read